Send to:

Choose Destination
See comment in PubMed Commons below
Curr Hematol Malig Rep. 2008 Oct;3(4):187-93. doi: 10.1007/s11899-008-0027-5.

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Author information

  • 1James P. Wilmot Cancer Center, Division of Hematology-Oncology, University of Rochester, 601 Elmwood Avenue,Box 704, Rochester, NY 14642, USA.


The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease. Several of the antibodies have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk